Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 16, 2011

Standard of Care, Overseas Opportunities Top Strategies Firms Use to Overcome MDX Reimbursement Issues

  • Exactly half of respondents to a GEN poll say their companies are working to gain provider acceptance and reimbursement for personalized medicine by pursuing standard-of-care status for their molecular diagnostics. Another third (33.3%) are concentrating their efforts on developing diagnostics for markets outside the U.S., while 16.7% said they are forming partnerships with the pharmaceutical industry. Steven Burrill, CEO of Burrill & Company, has likened gaining acceptance for personalized medicine diagnostics to hand-to-hand combat: “Investors were naïve at how substantial and perverse the resistance to adoption is.”



Related content

Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »